Clinical Updates for Specialty Pharmacists on PCSK9 Inhibitor Therapy
0290-0000-18-147-H01-P
This program presented by PTCE, with expert faculty, will enable participants to differentiate between the approved PCSK9 inhibitor therapies.
1.50
Improving Outcomes in Diabetic Retinopathy: A Specialty Pharmacy Discussion of Outcomes and Cost- Effectiveness
0290-0000-18-145-H01-P
This program presented by PTCE will address the appropriate identification of risk factors for diabetic retinopathy, as well as diabetic macular edema (DME)
1.50
The Future Direction of Managing Psoriatic Disease: Clinical Updates for Specialty Pharmacy
0290-0000-18-143-H01-P
Differentiating treatment regimens and exploring how to implement cost-effective therapies to improve quality of life for the patient will be some highlights discussed at this PTCE program.
1.50
Novel Immunotherapy Options for the Long-term Care of Patients with Chronic Lymphocytic Leukemia (CLL): The Role of Clinical and Specialty Pharmacists
0290-0000-18-140-L01-P
Pharmacists must focus on managing and counseling patients with CLL and healthcare professionals about adverse events and available novel immunotherapeutic options.
9-18-2018
1.50